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Fifteen lepromatous leprosy (LL) patients undergoing erythema nodosum leprosum (ENL) reactions were
compared with 13 stable, uncomplicated, anergic individuals of the same leprosy background. ENL patients
showed significant antigen-induced leukocyte migration inhibition (migration index = 0.058 + 0.01),
paralleling the values obtained with a responder tuberculoid leprosy population (migration index = 0.04 ±
0.004). Both phytohemagglutinin-induced general T-cell proliferation and, more significantly, antigen-induced
lymphoproliferation were enhanced during the acute phase of the reaction. Suppressor cell activity, monitored
by a costimulant assay, showed enhanced antigen-stimulated suppression of mitogen responses. Interestingly,
the improvement in in vitro T-celi responses was not reflected in dermal reactivity, since 48-h delayed-type
hypersensitivity responses after intradermal injection of soluble Mycobacterium leprae antigens continued to be
poor. After subsidence of reactional lesions, leukocyte migration inhibition, lymphoproliferation, and
suppressor cell activity were reduced to the unresponsive state seen in stable LL patients. Significantly,
perturbations of T-cell reactivity are detectable in ENL reactions, indicating the natural but transient
emergence of antigen-induced T cells in LL.
Lepromatous leprosy (LL), the disseminated form of
Mycobacterium leprae infection, exhibits selective, antigen-
specific T-cell unresponsiveness. LL patients have poor
delayed-hypersensitivity reactions and reduced lymphopro-
liferation in response to T-cell mitogens (3, 12) and M. leprae
antigens (7, 18). The nonspecific unresponsiveness noted in
some LL patients is reversed after chemotherapy, though
specific antigen-related anergy is persistent and long lasting
(12, 19). Enhanced B-cell functions have been reported in
LL (18). Immunoregulatory abnormalities due to enhanced
(11) or decreased (20, 22, 23, 32, 34) suppressor T-cell
activity and macrophage- (30) or monocyte-derived (31)
factors have been implicated in pathogenic mechanisms
underlying the defect in LL.
LL patients suffer from acute, episodic, exacerbated
reactional states called erythema nodosum leprosum (ENL),
which are characterized by crops of tender, erythematous,
subcutaneous nodules and systemic manufestations of
pyrexia, malaise, neuritis, arthralgia, and proteinuria. The
mechanisms underlying ENL have been attributed to im-
mune complex-mediated injury as evidenced by histo-
pathology (37), presence of immunoglobulin and comple-
ment in lesions (36), and circulating immune complexes (1, 5,
14) and complement-degradative products (1, 6).
In recent years, sporadic evidence of altered T-cell reac-
tivity in patients with ENL has been observed by us (22) as
well as others (27). The present study was undertaken in LL
patients to systematically evaluate the status of T-cell-
mediated functions during and after ENL reactions. Defini-
tive evidence for transient improvement in T-cell functions
was obtained in many LL patients during the acute phase of
ENL. Significantly, antigen-induced (i) leukocyte migration
inhibition, (ii) lymphoproliferation, and (iii) suppressor T-
cell activity were enhanced, indicating the presence or
emergence of antigen-reactive T cells in LL patients. After
subsidence ofENL lesions, most patients showed a return to
hyporeactivity or anergy associated universally with LL.
* Corresponding author.
Interestingly, the transient improvement in in vitro T-cell
functions was not associated with the appearance of skin
reactivity to concomitant intradermal injection of soluble M.
leprae antigens.
MATERIALS AND METHODS
Patients. Twenty-eight patients classified by the Ridley and
Jopling (29) scale were included in the study. Thirteen
patients had uncomplicated LL, whereas 15 presented with
erythematous, subcutaneous, tender crops of nodules on an
LL background and were taken as ENL patients. The clinical
details are given in Table 1.
Immunological studies were performed (i) during active
ENL, before initiation of antireaction therapy, as well as (ii)
1 week to 4 months after stopping treatment, when clinical
signs and symptoms of ENL had subsided. All patients were
subsequently treated with aspirin, thalidomide (300 mg
daily), and clofazimine (300 mg daily), with or without
prednisolone (20 to 30 mg daily). All drugs were gradually
reduced, and patients were maintained on clofazimine (100
mg on alternate days) along with dapsone (100 mg daily) and
rifampin (1,200 mg monthly).
Stimulants. (i) Autoclaved, armadillo-derived M. leprae
(lepromin A), kindly supplied by R. J. W. Rees, NIMR,
London, was used in the leukocyte migration inhibition test.
(ii) M. leprae extracted from skin biopsies from bacilliferous
LL patients as described earlier (25) were used for the
lymphoproliferative and suppressor cell assay. In brief, the
tissue was homogenized in glass homogenizers in RPMI 1640
after prior removal of the epidermis. Extracted bacilli were
screened for the absence of other contaminating bacteria by
culturing on (i) nutrient agar for 72 h and (ii) Lowenstein-
Jenson medium for 8 weeks. The bacilli were counted by the
standard method described earlier (8). Three concentrations
of antigen were used for each patient for lymphoproliferative
assays; 1.25 x 104, 1.25 x 105, and 1.25 x 106 M. leprae were
added for 100 ,ul of 105 peripheral blood monocytes (PBMC)
per well. The data are expressed for the optimal response at
a given antigen concentration. In general, 1.25 x 105 bacilli
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TABLE 1. Clinical details of 15 ENL patients
Clinical signs and symptoms Patients
affected
Subcutaneous nodules
Erythema .................................................
Tenderness ...............................................
Nerves (1-4)
Thickening.. .............................................
Tenderness ...............................................
Constitutional symptoms
Fever .....................................................
Joint pains................................................
Edema
...................................................
Hypoanesthesia ...........................................
Eye involvement ..........................................
100
86
66
40
86
73
53
40
13
per well was optimal for lymphocyte responses of responder
tuberculoid patients. (iii) Sonicated M. leprae (108 bacilli per
ml) were prepared in an ultrasonic power unit (M. S. E.
Scientific Instruments) for 60 min. Dilutions corresponding
to the bacterial concentrations mentioned above were pre-
pared in RPMI 1640 medium and filter sterilized (0.45-,um
[pore size] membrane filter; Millipore Corp., Bedford,
Mass.) before use. (iv) Phytohemagglutinin-P (PHA-P;
Sigma Chemical Co., St. Louis, Mo.) was used at optimal
(200 p,g/ml) and suboptimal (20 ,ug/ml) concentrations (as
tested on control subjects) for both lymphoproliferative and
suppressor cell assays.
Leukocyte migration inhibition assay. The methodology
used was a modification of the techniques described earlier
(10). Leukocytes obtained from heparinized (10 IU of pre-
servative-free heparin; Microlabs, Bombay, India) venous
blood were washed twice with Hanks balanced salt solution
(Microlabs) and suspended at 4 x 107 to 5 x 107 cells per ml
in RPMI 1640 medium (GIBCO Laboratories, Grand Island,
N.Y.) containing 20 mM N-2-hydroxyethylpiperazine-N'-2
ethanesulfonic acid, 100 IU of penicillin per ml, and 100 pg
of streptomycin per ml. One portion of the cell suspension
was incubated with medium only (RPMI 1640), and the other
was incubated with 108 M. leprae. Both portions were
incubated at 37°C for 1 h with humidified 5% CO2 in air.
Subsequently, 20-,ul capillaries (Arthur H. Thomas Co.,
Philadelphia, Pa.) were charged with test and control cell
suspensions, centrifuged at low speed for 2 min, and cut just
below the cell-supernatant interphase. Cells were then al-
lowed to migrate for 16 h at 37°C in migration chambers
(Laxbro; Pune, India) filled with RPMI 1640 and 10% fetal
calf serum (Microlabs) in an atmosphere of 5% CO2 in air.
Four replicates of control and antigen-treated leukocytes
were set up. The area of migration of leukocytes was
measured by projection on a screen. The migration index
(MI) was calculated as: MI = (area of migration with
antigen)/(area of migration without antigen).
Separation of PBMC. PBMC were isolated from sterile,
heparinized venous blood by Ficoll-Paque (Pharmacia Fine
Chemicals, Piscataway, N.J.) density gradient centrifugation
(2). After the cells were washed twice with Hanks balanced
salt solution, they were suspended at a concentration of 106
cells per ml in RPMI 1640 containing 10% autologous
plasma.
Lymphoproliferation assay. Quadruplicates of 105 PBMC
in 100 p.l of medium and 25 p.l of (i) medium, (ii) suboptimal
PHA-P, (iii) optimal PHA-P, (iv) integral antigen at 1.25 x
105, (v) integral antigen at 1.25 x 106, (vi) integral antigen at
1.25 x 107, and (vii, viii, and ix) sonicated antigens corre-
sponding to iv, v, and vi were set up in round-bottomed
microculture plates (Nunc, Roskilde, Denmark). The cells
were incubated at 37°C in 5% CO2 and air. Mitogen and
antigen cultures were terminated after 72 and 144 h, respec-
tively. The cells were harvested onto glass fiber discs by a
semiautomatic cell harvester (Ilacon, Tonbridge, U.K.) 18 to
20 h after the addition of 0.5 ,uCi of [3H]thymidine (specific
activity, 1.80 Ci/mmol; Bhabha Atomic Research Centre,
Trombay, India). Radioactivity was counted in a Rackbeta II
1215 scintillation counter (LKB Instruments, Inc., Rock-
ville, Md.). The counts per minute (cpm) ± the standard
error of replicate cultures were calculated, and the degree of
proliferation (Acpm) was derived as: Acpm = cpm in stimu-
lated cultures - cpm in unstimulated cultures.
Suppressor cell assay. The costimulant assay described
earlier (22) from our laboratory was used with the proviso
that PHA-P was used as a mitogen instead of concanavalin A
(Pharmacia). In brief, quadruplicate cultures were set up.
One-hundred-microliter volumes of 105 PBMC per well were
cultured with (i) 25 RI of RPMI 1640, (ii) 25 RI of integral or
sonicated M. leprae antigen (5 x 106 bacilli per ml), (iii) 25 [lI
of antigen followed by 25 pl1 of PHA-P (20 ,ug/ml), (iv) 200
pI/ml 24 h later, or (v) 25 plI of PHA-P at the same time as in
iii and iv. Cultures were harvested at 72 h after mitogen
addition, after 18 to 20 h or prior pulsing with 0.5 puCi of
[3H]thymidine as described above. Percent suppression was
calculated as follows: Percent suppression [(cpm with
mitogen - cpm with mitogen-antigen)/(cpm with mitogen +
cpm with antigen)] x 100.
Characterization of PBMC. T cells. Indirect immunofluo-
rescence with murine monoclonal antibodies (OKT series,
orthoclone; Ortho Diagnostics, Inc., Raritan, N.J.) and
fluorescein isothiocyanate-conjugated F(ab')2 anti-mouse
fragments (New England Nuclear Corp., Boston, Mass.)
were used for enumerating T cells and their subsets. Five
microliters of OKT3 (pan T cell), OKT4 (helper-inducer
subset), and OKT8 (suppressor-cytotoxic subset) was added
to 106 PBMC in 100 pI of RPMI 1640 containing no plasma.
The cells were incubated for 30 min at 4°C, washed twice,
suspended in a 1OO-pI volume, and exposed to 5 RIl of the
second antibody for 60 min at 4°C. Subsequently, the cells
were washed twice and counted by viewing under a Zeiss
universal microscope (Carl Zeiss, Oberkochen, Federal Re-
public of Germany) with epi-illumination with an HBO 50
mercury lamp, excitation filter BP 450-490, and barrier filter
BP 520-560. A minimum of 200 cells were counted for each
sample.
B cells. The presence of surface immunoglobulin was used
for B-cell enumeration. Briefly, 105 cells were exposed to 50
pI of 1:40 fluorescein isothiocyanate-conjugated rabbit anti-
human immunoglobulins (immunoglobulin G [IgG] + IgM +
IgA; Cappel Laboratories, Cochranville, Pa.) for 60 min at
4°C, washed, and enumerated as described above.
Skin test. Soluble, armadillo-derived M. Ieprae antigen
(100 pul) (leprosin A; 10 pug/ml) was injected intradermally on
the volar aspect of the forearm. Induration was measured 48
h later, and diameters of <10 mm were regarded as negative.
Statistical analysis. The data were analyzed by the Mann-
Whitney U test (33).
RESULTS
The clinical features of 15 LL patients undergoing ENL
reactions are given in Table 1. Of these patients, 7 were
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TABLE 2. In vitro responses in tuberculoid and LL patients
Mean ± SEM (no. of patients)
Diagnosis Acpm with: % Suppression with:MI
PHA-P(s)a PHA-P(o)b IBc SBd IBc SBd
Tuberculoid 0.04 ± 0.004 (6) 7,657 ± 1,146 (8) 31,385 ± 3,837 (8) 3,317 ± 489 (9) 3,767 ± 458 (7) 57.7 ± 6.7 (8) 48.3 ± 4.9 (7)
leprosy
LL 0.86 ± 0.10 (8) 662 ± 187 (10) 14,544 ± 2,833 (9) 51 ± 96 (9) 85 ± 89 (8) 10.8 ± 7.5 (9) 10.78 ± 3.6 (9)
a Suboptimal PHA-P concentration.
b Optimal PHA-P concentration.
IB, Integral bacilli.
d SB, Sonicated bacilli.
available for follow-up studies 1 week to 4 months after
subsidence of clinical signs of ENL and completion of
specific antireaction therapy. Treatment with combination
antileprosy drugs was continued throughout. For compari-
son, 13 LL patients with the stable form of the disease and
without a history of earlier reactions were included in the
study. Tuberculoid leprosy patients formed the baseline
control group used to evaluate the level of responsiveness to
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FIG. 1. Immunological responses in LL (L) and ENL (LR)
patients. (a) Leukocyte migration inhibition factor production in the
presence of M. leprae antigens. MI, Ratio of area of migration of
leukocytes in the presence and absence of antigen. (b) Lymphopro-
liferative response of PBMC in the presence of suboptimal (0, 0)
and optimal (0, O) concentrations of PHA-P. Acpm, cpm in
stimulated cultures minus cpm in tinstimulated cultures. (c) Lym-
phoproliferative response of PBMC in the presence of integral (A,
A) and sonicated (A, A) M. leprae antigens. (d) Suppressor cell
M. leprae antigens in leprosy as a whole. Integral and
membrane-filtered sonicated bacillary antigens were used to
evaluate responses to surface and cytoplasmic antigens,
respectively. Three concentrations of the antigens corre-
sponding to suboptimal, optimal, and supraoptimal bacillary
numbers were used for both antigens to cover any dose-
related differences in the lymphoproliferative responses.
Only optimal responses are included in the results.
Nonreactional, stable leprosy. Whereas tuberculoid leprosy
patients showed optimal responses to PHA-P and M. leprae
antigens (Table 2), all LL patients showed a lack of antigen-
induced leukocyte migration inhibition (Fig. la) and lympho-
proliferative in vitro responses to soluible and integral M.
leprae antigens (Fig. lc). Moreover, the majority of LL
patients showed poor mitogen responses (Fig. lb). In con-
formity with our earlier observations with concanavalin A as
mitogen (22), stable LL patients showed no or poor inhibi-
tion of mitogen responsiveness in the presence of both types
of M. leprae antigen (Fig. ld).
Active ENL. Leukocyte migration inhibition test. Nine
patients tested during active ENL and before institution of
specific antireaction therapy gave evidence of strong anti-
gen-induced leukocyte mnigration inhibition in response to
heat-killed integral M. leprae (Fig. la). The mean MI for the
ENL group (MI = 0.058 ± 0.01) was significantly different (P
<0.005) from that of control LL patients who showed the
expected unresponsiveness (mean MI = 0.86 ± 0.10). Inter-
estingly, the level of migration inhibition in the ENL group
matched the levels attained in responder tuberculoid leprosy
individuals (Table 2). Three patients tested within a week of
initiation of antireaction therapy showed abrogation of mi-
gration inhibition (mean MI = 0.39 ± 0.10).
Lymphoproliferative responses. We evaluated mitogen-
induced lymphoproliferation at both suboptimal (20 ,ug/ml)
and optimal (200 p.gIml) concentrations of PHA-P with a
view to cover dose-related alterations, if any, in T-cell
responsiveness during acute ENL. Some ENL patients
showed enhanced mitogen responsiveness compared with
the nonreactional group at both concentrations of PHA-P
(Fig. lb). The mean Acpm + the standard error for the ENL
activity generated by integral (O, [E) and sonicated (-, El) M. leprae
antigens as assessed by their effect on lymphoproliferation in
response to a suboptimal concentration of PHA-P. Percent
suppression was calculated as: percent suppression = [(cpm in the
presence of mitogen - cpm in the presence of antigen-mitogen)/(cpm
in the presence of mitogen + cpm in the presence of antigen)] x 100.
Values obtained with individual patients are depicted by vertical lines
showing the mean + standard error of the mean. * , Values above
50,000 cpm.
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TABLE 3. Characterization of PBMC from LL and ENL patients
Leprosy type Range (mean ± SE) of % of cells characterized as:
(no. of patients) OKT3+ SIg+a OKT4+ OKT8+
LL (10) 48-80 (59.7 ± 1.7) 18-26 (21.5 ± 1.0) 25-51 (33.7 ± 2.5) 12-38 (22.4 ± 2.86)
ENL (9) 58-80 (67.67 ± 1.8) 21-27 (22.8 ± 0.09) 16-41 (30.6 ± 0.96) 31-52 (38.11 ± 2.46)
a SIg+ cells are B cells.
group were 2,669 ± 809 and 30,478 ± 6,707, respectively, for
the lower and higher concentrations of PHA-P.
Of greater significance was the detection of antigen-
induced in vitro lymphoproliferation to M. Ieprae antigens of
9 of 11 patients undergoing ENL reactions (Fig. ic). Respon-
siveness to both integral and soluble antigens in the ENL
group was significantly higher (P <0.01) compared with the
uncomplicated LL group. However, the degree of prolifer-
ation observed in ENL patients was relatively lower than
that seen in the tuberculoid responder group (Table 2). The
mean zAcpm with integral and soluble antigens in the ENL
group were 1,331 ± 286 and 2,495 ± 557, respectively.
Suppressor cell activity. Antigen-induced suppressor cell
activity was assessed in a costimulant assay as described
earlier (22), whereby the effect of integral and sonicated
antigens on mitogen responses of the patients were graded.
Fig. ld gives individual data for both antigens for both
groups of patients. The mean percent suppression in the
stable LL group was 10.8 ± 7.1 and 10.78 ± 3.59% with
integral and soluble antigens, respectively. ENL patients
showed significant enhancement of suppression, the mean
percent suppression being 28.9 ± 4.7 and 32.4 ± 5.4% for
integral (P <0.01) and sonicated (P <0.05) antigens, respec-
tively. This increase in suppression noted in ENL was only
observed when suboptimal PHA-P was used. The degree of
suppression induced by the two antigen preparations showed
no differences between the stable LL and ENL groups when
the optimal PHA-P concentration was used in the assay.
Lymphocyte subsets. T-cell subsets in the PBMC of both
groups of patients were characterized by indirect immuno-
fluorescence with monoclonal antibodies OKT3, OKT4, and
OKT8. Nine ENL patients showed an increase in OKT8+
cells with a significantly (P <0.05) lower OKT4/OKT8 ratio
(0.81 ± 0.1) compared with that observed in patients with
uncomplicated LL (1.68 + 0.25) (Table 3). B-cell percent-
ages in the PBMC of ENL patients were similar to those of
uncomplicated LL individuals (Table 3).
Delayed-hypersensitivity reaction. All patients with ENL
showed absence of erythema and induration 48 h after
intradermal injection of soluble armadillo-derived M. leprae
antigens (10 Fxg/ml). This lack of responsiveness paralleled
the anergy observed in nonreactional LL patients (Table 4).
Post-ENL status. Of the ENL patients, 7 were tested after
subsidence of lesions and termination of reaction-specific
TABLE 4. Comparison of delayed-type hypersensitivity
responses to leprosin A and leukocyte migration inhibition test
performed with lepromin A in ENL patientsa
Leprosy Skin induration ml
type diam (mm)
LL 0-0 (0 ± 0) (7) 0.39-1.34 (0.86 ± 0.10) (8)
ENL 0-0 (0 ± 0) (9) 0.01-0.16 (0.06 + 0.01) (9)
a First set of values in parentheses is the mean ± standard error; second set
of values in parentheses is the number of patients.
therapy. All patients showed a reversal of the T-cell reactiv-
ity observed during active ENL (Fig. 2). The levels of MI,
(Fig. 2a), lymphoproliferative responses (Fig. 2b and c), and
suppressor activity (Fig. 2d) in post-ENL patients were
similar to those observed in the control group of patients
with uncomplicated LL.
DISCUSSION
The present study provides evidence for the natural emer-
gence of transient T-cell reactivity in hitherto anergic LL
patients during the reactional phase of ENL (16). Signifi-
cantly, both lymphoproliferative and lymphokine-related in
vitro T-cell responses to M. leprae antigens were detectable
in many ENL patients. The degree of leukocyte migration
inhibition in the acute phase of the reaction was similar to
that obtained with cells from responder tuberculoid leprosy
patients. Of the 11 ENL individuals, 9 showed significant
lymphoproliferative responses in the presence of both solu-
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FIG. 2. Immunological studies during the postreactional phase in
ENL patients. Symbols: l, During reaction; 0, postreaction. (a)MI.
(b) Acpm with suboptimal and optimal concentrations of PHA-P. (c)
Acpm with integral (IB) and sonicated (SB) bacilli. (d) Percent
suppression at suboptimal and optimal concentrations of PHA-P.
Values obtained with individual patients are depicted.
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ble and integral M. leprae antigens. However, the level of
proliferation was of a moderate degree and did not reach the
levels usually observed with tuberculoid leprosy individuals.
Our results also confirm earlier reports of enhanced mito-
genic responses in LL patients undergoing ENL reactions
(15, 35). ENL lesions are known to frequently show frag-
mented bacilli (28). It is possible that the transient increase
in T-cell reactivity may play a role in bacterial killing.
Suppressor T-cell activity was evaluated in leprosy pa-
tients in a costimulant assay (22), whereby the effect of
antigens on the mitogenic responses of PBMC was mea-
sured. We (20, 22, 23), as well as others (4, 32, 34), had
reported that LL patients showed low or absent M. leprae-
induced' suppressor cell activity on concanavalin A re-
sponses during the stable form of the disease compared with
healthy responder individuals and tuberculoid patients.
However, one report showed contrary results of increased
T8+ suppressor T-cell function in LL (11). With a view to
investigating further the suppressor mechanisms in this
disease, we used PHA as the T-cell mitogen and soluble and
integral human-derived M. leprae as antigens in the in vitro
assay. The present results confirm our earlier findings of a
lack of suppressor T-cell activity in the stable form of the
disease. Interestingly, suppressor function developed con-
comitantly with the emergence of antigen- and mitogen-
responsive T cells in patients in the acute phase of ENL.
Whereas >20% suppression ofPHA-P responses was seen in
7 of 12 ENL patients, only 2 of the stable LL patients
showed similar levels of suppression. In general, the type of
antigen used in the costimulant assay was not found to be an
important factor in the generation of suppression. However,
the concentration of the mitogen was important, since no
difference between stable and reactional patients was ob-
servable at the optimal PHA-P concentration (200 p.g/ml).
Dose-related differences in levels of suppression obtained
have been reported earlier with concanavalin A as a mitogen
(32).
Furthermore, olir ENL patients showed a relative in-
crease in OKT8+ cells as indicated by the lowered
OKT4/OKT8 ratio in ENL in comparison with stable LL
patients. Variable results have been reported regarding
T-cell subsets in ENL. Whereas some authors have reported
unaltered proportions of T-cell subsets (26), others have
found a reduction of the OKT8+ subset (15, 35). Some of
these differences may be related to the stage of ENL at the
time of study, ethnic differences, and methodological vari-
ables for the detection of phenotype-positive cells.
The enhanced antigen-induced T-cell reactivity observed
in vitro was not reflected in vivo after concomitant intrader-
mal challenge with soluble M. leprae antigens. Lack of skin
test reaction was noted both during and after ENL reactions,
though the same batch of antigen showed positive reactions
in tuberculoid leprosy patients (mean induration = 21.75
mm). It is possible that (i) there is a time lag before the
changes observed in circulation are reflected in tissues, (ii)
different antigenic determinants are involved in in vivo and
in vitro responses, and (iii) more than one type of delayed
hypersensitivity exists in leprosy. This persistent lack of
dermal reactivity is particularly intriguing, since significant
increases in numbers of T4+ T cells have been detected in
ENL lesions by us (17) and others (13), thereby ruling out
any major inherent defect in the traffic of T cells into leprosy
lesions.
The presence of antigen-reactive T cells in anergic LL
patients has been recently shown by us (21) and others (9,
24). The emergence of T-cell reactivity, albeit transiently, in
ENL patients is a further indication that M. leprae-
responsive T cells are present in unresponsive LL. ENL
appears to be a natural model for the study of immunological
perturbations that occur against a background of LL. Histo-
logical evidence of bacillary fragmentation in ENL lesions
suggests that these transient immunological phenomena are
of biological significance. Whether immunoregulatory phe-
nomena, immune complexes, or altered or hidden antigenic
determinants of M. leprae precede the development of T-cell
reactivity is unclear, since it was not feasible to study the
patients before the development of clinical signs. However,
systematic follow-up of the natural course of disease in
reactional patients and the dissection of the immunological
mechanisms that are responsible for the emergence of anti-
gen-reactive T cells in LL would have far-reaching implica-
tions for the understanding and treatment of this disease.
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